Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 8/20 | 0.57 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.57 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.57 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.57 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.57 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.57 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.57 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.48 |
| ▸ | GABRP | O00591 | 6/20 | 0.48 |
| ▸ | GABRD | O14764 | 6/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.48 |
| ▸ | GABRE | P78334 | 6/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.48 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.48 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31172628 | 0.82 | CYP1A2 (0.55) | GABRA2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL82426 | 0.82 | CYP1A2 (0.55) | GABRA2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL1971939 | 0.81 | MAPK1 (0.61) | GABRA2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL29637478 | 0.81 | MAPK1 (0.61) | GABRA2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL229176 | 0.81 | CA12 (0.55) | GABRA2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL10003611 | 0.81 | CYP1A2 (0.53) | GABRA2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL5845581 | 0.80 | MAPK1 (0.65) | GABRA2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL31354658 | 0.80 | MAPK1 (0.65) | GABRA2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL347328 | 0.79 | CYP1A2 (0.51) | GABRA2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL754777 | 0.79 | CYP1A2 (0.56) | GABRA2GABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595483-B1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9186354-B2 | Pyrrolidine derived β3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140315912-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2014-10-23 | — | — | US | disclosed |
| EP-2595483-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | Merck Sharp & Dohme Corp. (US) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012012314-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315912-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | GABRA2 161/4885GABRA1 163/4885GABRG2 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.